Chemotherapy Induced Anemia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Anemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2014', provides an overview of the Chemotherapy Induced Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Chemotherapy Induced Anemia - Overview 8
Pipeline Products for Chemotherapy Induced Anemia - Comparative Analysis 9
Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10
Chemotherapy Induced Anemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Chemotherapy Induced Anemia - Products under Development by Companies 15
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16
Eli Lilly and Company 16
3SBio Inc. 17
ProMetic Life Sciences Inc. 18
Avesthagen Limited 19
Therapure Biopharma Inc. 20
Tarix Pharmaceuticals LTD. 21
Aprogen, Inc. 22
Tolero Pharmaceuticals, Inc. 23
SBI Pharmaceuticals Co., Ltd. 24
Chemotherapy Induced Anemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
epoetin alfa - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PBI-1402 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LY-2787106 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
aminolevulinic acid hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NuPIAO - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
darbepoetin alfa - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PanCyte - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PBI-4494 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TBI-304 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
darbepoetin alfa - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
TP-0413 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Chemotherapy Induced Anemia - Recent Pipeline Updates 48
Chemotherapy Induced Anemia - Dormant Projects 50
Chemotherapy Induced Anemia - Discontinued Products 51
Chemotherapy Induced Anemia - Product Development Milestones 52
Featured News & Press Releases 52
Sep 20, 2013: Approval of Long-Acting Erythropoiesis-Stimulating Agent NESP Injection 5�g Plastic Syringe in Japan 52
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 52
Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 52
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 53
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 53
Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 54
Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 55
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 55
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 56
Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H2 2014 8
Number of Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Chemotherapy Induced Anemia - Pipeline by Eli Lilly and Company, H2 2014 16
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2014 17
Chemotherapy Induced Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2014 18
Chemotherapy Induced Anemia - Pipeline by Avesthagen Limited, H2 2014 19
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2014 20
Chemotherapy Induced Anemia - Pipeline by Tarix Pharmaceuticals LTD., H2 2014 21
Chemotherapy Induced Anemia - Pipeline by Aprogen, Inc., H2 2014 22
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 23
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Chemotherapy Induced Anemia Therapeutics - Recent Pipeline Updates, H2 2014 48
Chemotherapy Induced Anemia - Dormant Projects, H2 2014 50
Chemotherapy Induced Anemia - Discontinued Products, H2 2014 51